Phaseline

Companies › Ascentage Pharma Group

Ascentage Pharma Group: clinical trials, targets and expected readouts

8 active drug programs in 40 registered trials: 23 Phase 1, 9 Phase 2, 8 Phase 3; Oncology, Hematology, Other, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apg-2575
Apoptosis regulator Bcl-2 inhibitor
BCL2Phase 3CLL/SLL; Acute Myeloid Leukemia; Higher-risk Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia …Dec 2026
Olverembatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3GIST; Chronic Myeloid Leukemia; Ph+ ALL; Pharmacokinetic …Mar 2027
APG-115
MDM2 inhibitor
MDM2Phase 2T-Prolymphocytic Leukemia; Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Liposarcoma; Neuroblastoma …Jan 2027
APG-2449
Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor
FAK, ALK, ROS1Phase 1Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid CancerMay 2027
APG-5918
HIF-PHD inhibitor
PHD1, PHD2, PHD3Phase 1AnemiaDec 2027
APG-3288
Dual BCL-2 and MCL-1 inhibitor
BCL2, MCL1, BCL-XLPhase 1Relapsed/Refractory Hematological MalignanciesDec 2029
APG-1252
BCL-2 family protein inhibitor
BCL2, BCL2L1, BCL2L2, MCL1Phase 1EGFR Positive Non-small Cell Lung Cancer–
Osimertinib Mesylate (AZD9291)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1EGFR Positive Non-small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04494503Apg-2575Phase 1Chronic Lymphocytic LeukemiaOncologyOct 2024
NCT04001777APG-1252Phase 1EGFR Positive Non-small Cell Lung CancerOncologyDec 2025
NCT04001777Osimertinib Mesylate (AZD9291)Phase 1EGFR Positive Non-small Cell Lung CancerOncologyDec 2025
NCT03611868APG-115Phase 1Unresectable or Metastatic Melanoma or Advanced Solid TumorsOncologyDec 2025
NCT07282093OlverembatinibPhase 1PharmacokineticOtherJun 2026
NCT06757855OlverembatinibPhase 1CML,Blast PhaseOncologyDec 2026
NCT05147467Apg-2575Phase 2Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT06182969Apg-2575Phase 1SLEImmunologyDec 2026
NCT05495035OlverembatinibPhase 1Lymphoblastic Leukemia, Acute, ChildhoodOncologyDec 2026
NCT06104566Apg-2575Phase 3CLL/SLLOncologyDec 2026
NCT03913949Apg-2575Phase 1Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT05495035Apg-2575Phase 1Lymphoblastic Leukemia, Acute, ChildhoodOncologyDec 2026
NCT06401603OlverembatinibPhase 1Advanced Chronic Myeloid LeukemiaOncologyJan 2027
NCT04785196APG-115Phase 1LiposarcomaOncologyJan 2027
NCT03781986APG-115Phase 1Malignant Salivary Gland CancerOncologyJan 2027
NCT06817720OlverembatinibPhase 2Chronic Myeloid LeukemiaOncologyMar 2027
NCT06640361OlverembatinibPhase 3GISTOncologyMar 2027
NCT06687070APG-2449Phase 1Platinum-resistant Recurrent Ovarian CancerOncologyMay 2027
NCT04496349Apg-2575Phase 2T-Prolymphocytic LeukemiaOncologyMay 2027
NCT04496349APG-115Phase 2T-Prolymphocytic LeukemiaOncologyMay 2027
NCT05701306Apg-2575Phase 1NeuroblastomaOncologyJun 2027
NCT05701306APG-115Phase 1NeuroblastomaOncologyJun 2027
NCT06423911OlverembatinibPhase 3Chronic Myeloid LeukemiaOncologyJun 2027
NCT04215809Apg-2575Phase 1CLL/SLLOncologyJun 2027
NCT06319456Apg-2575Phase 3CLL/SLLOncologyAug 2027
NCT05521204OlverembatinibPhase 2Myeloproliferative NeoplasmOncologyAug 2027
NCT03594422OlverembatinibPhase 1Gastrointestinal Stromal Tumor (GIST)OncologyDec 2027
NCT03917043APG-2449Phase 1Advanced Solid CancerOncologyDec 2027
NCT06754267OlverembatinibPhase 2Precursor B-Cell Acute Lymphoblastic LeukemiaOncologyDec 2027
NCT06051409OlverembatinibPhase 3Ph+ ALLOncologyDec 2027
NCT05773586APG-5918Phase 1AnemiaHematologyDec 2027
NCT06220487OlverembatinibPhase 2Acute Lymphoblastic LeukemiaOncologyJan 2028
NCT06389292Apg-2575Phase 3Acute Myeloid LeukemiaOncologyMay 2028
NCT07272499Apg-2575Phase 2Mantle Cell Lymphoma (MCL)OncologySep 2028
NCT04501120Apg-2575Phase 1Relapsed/Refractory Acute Myeloid LeukaemiaOncologySep 2028
NCT07255963Apg-2575Phase 2DLBCL - Diffuse Large B Cell LymphomaOncologySep 2028
NCT06641414Apg-2575Phase 3Higher-risk Myelodysplastic SyndromeHematologyJun 2029
NCT07152041OlverembatinibPhase 3Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)OncologyDec 2029
NCT07424833APG-3288Phase 1Relapsed/Refractory Hematological MalignanciesOncologyDec 2029
NCT04260022OlverembatinibPhase 1Leukemia, Myeloid, ChronicOncologyDec 2029

From the company's SEC filings

Cash of 893m CNY on 2024-12-31; operating cash outflow about 111m CNY a year; runway about 96 months at that burn, to Jan 2033; 6 of 6 coming phase 2-3 readouts fall inside that runway

Targets

BCL2 (3) MCL1 (2) ABL1 (1) BCR (1) MDM2 (1) BCL-XL (1) FAK (1) ALK (1) ROS1 (1) PHD1 (1) PHD2 (1) PHD3 (1)

Companies with the same targets

AbbVie BeOne Medicines Il-Yang Pharm. Takeda Incyte Biosciences International Sàrl Enliven Therapeutics Novartis Taiho Pharmaceutical Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Otsuka

Companies built like this

Hutchmed Nuvation Bio Cogent Biosciences Corvus Pharmaceuticals Taiho Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.